As a whole, parasitic diseases affect an exorbitant number of people worldwide but are often overlooked as they are rare in more developed regions. Additionally, many of these neglected diseases have unusual pathology, making them incredibly difficult to manage therapeutically. Yet now, an international team of investigators led by scientists at George Washington University (GW) has successfully used the gene-editing tool CRISPR/Cas9 to limit the impact of parasitic worms responsible for schistosomiasis and liver fluke infections—which can cause a diverse spectrum of human disease including bile duct cancer.

The findings were published recently through two new studies in eLife. The first article entitled “Programmed genome editing of the omega-1 ribonuclease of the blood fluke, Schistosoma mansoni” and the other “Programmed knockout mutation of liver fluke granulin attenuates virulence of infection-induced hepatobiliary morbidity.”

George Washington University researchers “knocked out” the omega-1 ribonuclease protein using CRISPR/Cas9 and found that it greatly reduced the impact of schistosomiasis. [GW School of Medicine and Health Sciences]
“The genes we ‘knocked out’ using CRISPR/Cas9 resulted in markedly diminished symptoms of infection in our animal models,” explained senior study investigator on both papers Paul Brindley, PhD, professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences. “Our research also showed that this revolutionary new biomedical procedure—CRISPR/Cas9—can be adapted to study helminth parasites, which are a major public health problem in tropical climates.”

The impact that CRISPR is having with respect to studying various diseases cannot be understated. This technology allows researchers to precisely target and deactivate the genetic information needed to produce a particular protein. While the tool has been used in other species before, it was unknown if it could be applied to Schistosoma mansoni and Opisthorchis viverrini, the parasites responsible for schistosomiasis and liver fluke infections, respectively.

Schistosomiasis can cause serious health problems, including damage to the liver and kidneys, infertility, and bladder cancer. The freshwater worms S. mansoni enter the human body by burrowing into the skin—once in the bloodstream, they move to various organs where they rapidly start to reproduce. The parasite’s eggs release several molecules, including a protein known as omega-1 ribonuclease, which can damage the surrounding tissues. The research team knocked out this protein using CRISPR/Cas9 and found that it greatly reduced the impact of the disease.

“Schistosome eggs were exposed to Cas9 complexed with guide RNA complementary to ω1 by electroporation or by transduction with lentiviral particles,” the authors wrote. “Some eggs were also transfected with a single-stranded donor template. Sequences of amplicons from gene-edited parasites exhibited Cas9-catalyzed mutations including homology-directed repaired alleles, and other analyses revealed depletion of ω1 transcripts and the ribonuclease. Gene-edited eggs failed to polarize Th2 cytokine responses in macrophage/T-cell co-cultures, while the volume of pulmonary granulomas surrounding ω1-mutated eggs following tail-vein injection into mice was vastly reduced.”

 

George Washington University researchers used CRISPR/Cas9 to deactivate the gene that codes for granulin and create parasites that can only produce very little of the protein, leading to markedly reduced symptoms of liver fluke infection.[GW School of Medicine and Health Sciences]

Liver fluke infection can cause a type of liver cancer called bile duct cancer, triggered by the presence of the worm O. viverrini. This parasite is transmitted through traditional Southeast Asian cuisines using uncooked or undercooked fish. Once inside the body, the parasite settles in the human liver and secretes a protein known as granulin that may encourage liver cells to multiply, raising the risk for cancer. The researchers used CRISPR/Cas9 to deactivate the gene that codes for granulin and create parasites that can only produce very little of the protein, leading to markedly reduced symptoms of liver fluke infection.

“These neglected tropical diseases affect more than a quarter of a billion people primarily living in Southeast Asia, sub-Saharan Africa, and Latin America,” concluded Brindley. “CRISPR/Cas9 is a tool that may be used to limit the impact of these infections. As we work to better understand how these parasites invade and damage our bodies through this new technology, we will find new ideas for treatment and disease control.”

This site uses Akismet to reduce spam. Learn how your comment data is processed.